Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage precision oncology company, has announced the closing of its previously announced registered direct offering, raising approximately $4.4 million in gross proceeds. The offering involved the sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at a price of $2.06 per share. In a concurrent private placement, the company also issued unregistered warrants to purchase up to an additional 2,135,923 shares at an exercise price of $2.27 per share. If fully exercised, these warrants could generate up to approximately $4.85 million in additional gross proceeds.
This capital raise is expected to support Lantern Pharma's ongoing development of its clinical pipeline, which includes several promising candidates. LP-184, an acylfulvene compound, is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. LP-284, a TC-NER targeting compound, is being evaluated in hematologic and solid tumors. Additionally, LP-300, a cisplatin/ethacraplatin analog, is currently being assessed in the HARMONIC Phase 2 trial targeting never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment.
Beyond its clinical programs, Lantern Pharma is leveraging its proprietary RADR platform, which uses artificial intelligence and machine learning to transform cancer therapy development. The company has also commercialized withZeta.ai, a multi-agentic AI co-scientist platform now available as a subscription-based research tool for the global biomedical and drug development community. This platform represents a new revenue stream for Lantern, potentially broadening its financial base beyond traditional funding rounds.
The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For more details on the offering and company updates, investors can visit the company's newsroom at https://ibn.fm/LTRN.
The implications of this funding are significant for the precision oncology field. Lantern Pharma's AI-driven approach aims to accelerate the identification of effective cancer therapies, potentially reducing development timelines and costs. The additional capital may help advance late-stage trials and expand the company's pipeline, offering hope for patients with difficult-to-treat cancers. Moreover, the commercialization of withZeta.ai could provide a sustainable revenue model, reducing reliance on dilutive financing and enabling long-term growth.
Investors and industry observers will be watching for updates on the HARMONIC trial and progress with LP-184 and LP-284. The success of these programs could validate the use of AI in oncology drug development, potentially reshaping how cancer therapies are discovered and brought to market.
